- Home
- ENLV vs PULM Comparison
ENLV vs PULM Comparison
Compare ENLV & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- PULM
- Stock Information
- Founded
- ENLV 2005
- PULM 2003
- Country
- ENLV Israel
- PULM United States
- Employees
- ENLV N/A
- PULM N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- PULM Health Care
- Exchange
- ENLV Nasdaq
- PULM Nasdaq
- Market Cap
- ENLV 23.7M
- PULM 20.5M
- IPO Year
- ENLV 1995
- PULM N/A
- Fundamental
- Price
- ENLV $1.07
- PULM $4.79
- Analyst Decision
- ENLV Strong Buy
- PULM
- Analyst Count
- ENLV 2
- PULM 0
- Target Price
- ENLV $10.00
- PULM N/A
- AVG Volume (30 Days)
- ENLV 1.2M
- PULM 11.3K
- Earning Date
- ENLV 08-29-2025
- PULM 08-06-2025
- Dividend Yield
- ENLV N/A
- PULM N/A
- EPS Growth
- ENLV N/A
- PULM N/A
- EPS
- ENLV N/A
- PULM N/A
- Revenue
- ENLV N/A
- PULM $369,000.00
- Revenue This Year
- ENLV N/A
- PULM N/A
- Revenue Next Year
- ENLV N/A
- PULM $134.88
- P/E Ratio
- ENLV N/A
- PULM N/A
- Revenue Growth
- ENLV N/A
- PULM N/A
- 52 Week Low
- ENLV $0.81
- PULM $1.78
- 52 Week High
- ENLV $2.10
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ENLV 41.31
- PULM 41.91
- Support Level
- ENLV $1.01
- PULM $4.65
- Resistance Level
- ENLV $1.13
- PULM $5.00
- Average True Range (ATR)
- ENLV 0.13
- PULM 0.17
- MACD
- ENLV -0.02
- PULM 0.06
- Stochastic Oscillator
- ENLV 8.04
- PULM 62.50
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).